CEO
"Driven by the positive results of the TICC trial, and its publication at the ASCO conference, we have accelerated the establishment of our commercial infrastructure in
This increased momentum requires a solid organization and internal processes. The changes we initiated some months ago have culminated with the certification of our ISO 13485:2016 quality management system.
With a higher focus on the market, we have redefined our future product portfolio, to launch multiple lndiTreat® products for each cancer entity, covering different therapy decision-making points and thus expanding our market opportunity. We are proud of having engaged two global leaders in gastrointestinal cancer for our
We are very confident we are on track to achieve our ambitious goals for this year and for 2022.
FINANCIAL HIGHLIGHTS
With a successful warrant subscription in
First half of 2021 (2021-01-01 until 2021-06-30) - the group
Net turnover for the period was 0 KSEK (0 KSEK).
Other operating income was 4 319 KSEK (6 011 KSEK)
The result before tax was -8 810 KSEK (-4 797 KSEK)
The result per share* was -
The solidity** was 94 % (81 %).
The cash and bank were 78 913 KSEK (30 070 KSEK).
*Earnings per share: Profit for the period divided by the average number of shares. Average number of shares for the first half year of 2021: 15 338 033 shares. Total number of shares in
**Equity ratio: Shareholder's equity divided by total capital.
Significant events during the second quarter 2021
- April:
The exercise price for warrants of series TO1 determined to
Board and management of 2cureX exercise all held warrants of series TO1 for
2cureX's CEO
- May:
Warrants of series TO1 were subscribed to approximately 96.75 percent and
- June:
2cureX appoints 2 new VP's to accelerate the commercial efforts.
Significant events after the period
- July:
2cureX receives its ISO 13485:2016 certification, an important milestone in the company's efforts towards bringing 3D-microtumors to routine clinical practice.
- August:
2cureX appoints Dr.
2cureX announces in press release, that it is now able to predict response to anti-angiogenic drugs with a modified version of its IndiTreat® technology.
For more information about 2cureX:
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com
This information is such that
----
About 2cureX
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors, tumoroids that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.
The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.
According to several published reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds
The company is listed on Nasdaq First North Growth Market in
Certified Adviser:
- https://www.industryarc.com/Research/Cancer-IVD-Market-Research-507107
- https://www.grandviewresearch.com/industry-analysis/oncology-companion-diagnostics-market
https://news.cision.com/2curex/r/2curex-publishes-interim-report-for-the-second-quarter-and-first-half-of-2021,c3403760
https://mb.cision.com/Main/16432/3403760/1459455.pdf
https://mb.cision.com/Public/16432/3403760/b49da8e9844f8786.pdf
(c) 2021 Cision. All rights reserved., source